Early within the COVID-19 pandemic, Nrf2 was identified as a potential therapeutic target due to the theoretical beneficial effects on the oxidative stress and inflammation caused by the SARS-CoV-2 virus [17,25]. The gene discussed is NFE2L2; the disease is COVID-19.